Introduction {#S1}
============

Stroke is a leading cause of disability worldwide ([@B22]; [@B27]). Over the past decade, a substantial decrease of stroke mortality was achieved largely due to advancements of acute stroke management such as use of statins ([@B8]; [@B33]). However, as a substantial proportion of stroke survivors suffer from long-term disability that imposes an enormous medical and societal burden ([@B39]; [@B6]), development of effective treatments to improve neurological function for stroke patients are of major importance.

RPh201, an extract of gum mastic, is being developed by Regenera Pharma for the treatment of various neurological diseases. Mastic and extracts of gum mastic have been extensively used as an herbal remedy and dietary supplement for many centuries ([@B19]). Accumulating evidence suggests that mastic gum extracts exert potent anti-inflammatory, anti-oxidative, anti-bacterial, and anti-cancer properties in various experimental diseases ([@B13]; [@B17]; [@B10]). *In vitro* and *in vivo* animal toxicology studies performed using RPh201 for up to 39 weeks have revealed no genotoxic effects or safety concerns ([@B29], [@B30]). Currently, clinical evaluations on the safety and therapeutic effects of RPh201 for patients with central nervous system (CNS) diseases are underway ([@B4]; [@B31]). In healthy volunteers and in patients with previous non-arteritic anterior ischemic optic neuropathy (NAION), RPh201 was found to be safe and well tolerated after repeat subcutaneous injection ([@B12]; [@B31]). A recent Phase 2 clinical trial shows that long-term RPh201 treatment improves visual function in patients with previous NAION, which highlights the therapeutic potential of RPh201 for CNS diseases ([@B31]). However, the therapeutic effects of RPh201 on stroke have not been explored. Thus, the present study was under taken to investigate whether post stroke RPh201 treatment improves neurological functional recovery in rats after embolic stroke.

Materials and Methods {#S2}
=====================

All experimental procedures were approved by the Institutional Animal Care and Use Committee of Henry Ford Hospital. All experiments and outcome assessments were performed by observers blinded to the treatments.

RPh201 is a 5% (w/w) formulation of the drug substance in National Formulary--grade cottonseed oil stabilized with butylated hydroxytoluene. Vehicle is National Formulary--grade cottonseed oil stabilized with butylated hydroxytoluene.

Animal Model {#S2.SS1}
------------

Male Wistar rats (Charles River Laboratories) 2--3 months old and weighing 350--400 g (*n* = 40) were subjected to embolic middle cerebral artery occlusion (MCAO), as previously described ([@B41]). Briefly, an arteriotomy was made on the external carotid artery (ECA) and a single clot (40 mm in length) obtained from a donor rat was placed at the origin of the MCA via an endovascular catheter. Three hours after MCAO, rats were evaluated using a 5 point Longa score (0 = no neurologic deficit, 1 = failure to extend left forepaw fully, 2 = circling to the left, 3 = falling to the left, and 4 = does not walk spontaneously) ([@B21]). Rats with a Longa score below 2 were excluded. Rats in the Sham group (*n* = 13) received the same surgical procedures but without clot placement.

Experimental Design and Treatments {#S2.SS2}
----------------------------------

To examine the effect of RPh201 on brain remodeling during stroke recovery rather than on the neuroprotection in acute stroke, rats were randomly assigned to 3 groups according to a pre-generated randomization schema: (1) RPh201 treatment (*n* = 20), (2) Vehicle treatment (*n* = 20), and (3) Sham (*n* = 13). RPh201 is a 5% (w/w) formulation of the drug substance in Vehicle (National Formulary--grade cottonseed oil stabilized with butylated hydroxytoluene). RPh201 at a dose of 20 μl or the same volume of Vehicle were subcutaneously (SC) administered twice a week starting at 21 days after MCAO, a time point in which infarction is fully developed and brain remodeling occurs ([@B5]; [@B9]). The dose of RPh201 was chosen based on previously conducted studies in rat models of stroke and vascular dementia (unpublished data). The current dosage is 16--120 times less than the doses used in the toxicology study in rats and is approximately equivalent to the 20 mg of RPh201 used in clinical trials according to the published dose conversion methods between rat and human ([@B28]; [@B30]; [@B31]). Rats were then divided into two cohorts for neurological function, histopathology, and immunochemistry evaluations at 2 weeks (35 days after MCAO, *n* = 5/group for ischemic rats, *n* = 4 for Sham rats) and 16 weeks (133 days after MCAO, *n* = 15/group for ischemic rats, *n* = 9 for Sham rats) after initiation of treatment. For labeling mitotic cells, bromodeoxyuridine (BrdU, 100 mg/kg, Sigma) was administered (i.p) daily for 7 consecutive days starting at 21 days after stroke or Sham operation.

Neurological Outcome {#S2.SS3}
--------------------

Acute neurological outcome was evaluated at 3 h after MCAO using a 5 point Longa score ([@B21]; [@B43]). Neurological outcome was also evaluated in all rats with modified neurological severity scores (mNSS), foot-fault test, and adhesive removal test performed at 1, 7, 14, 21, 28, 60, 90, and 120 days after MCAO or until the designated endpoints.

mNSS {#S2.SS4}
----

For a composites core of stroke induced impairments on motor, sensory, reflex, and balance ability, mNSS was graded on a scale of 0 (normal) to 18 (maximal deficit), as previously described ([@B2]).

Adhesive Removal Test {#S2.SS5}
---------------------

Rats were tested for the responsiveness to forelimb somatosensory stimulation with the adhesive removal test. Briefly, 2 pieces of adhesive-backed paper (113.1 mm^2^) were used as bilateral tactile stimuli occupying the distal-radial region on the wrist of each forelimb for up to 28 days after stroke onset ([@B34]). Thereafter, half-sized stimuli (56.6 mm^2^) were used to increase the difficulty of the adhesive removal test starting 60 days post stroke. The mean time (seconds) required to remove the adhesive tab from the left forelimb was recorded with a cut off time at 120 s.

Foot-Fault Test {#S2.SS6}
---------------

Rats were tested for placement dysfunctions of forelimbs with the foot-fault test ([@B15]). The total number of steps (movement of each forelimb) that the rat used to cross the grid and the total number of foot-faults (fall or slip between the wires) for the left forelimb were recorded. Data are presented as a percentage of left foot-faults.

Infarct Volume Measurement {#S2.SS7}
--------------------------

For rats enrolled into the 16 week treatment cohort, ischemic (*n* = 7 in Vehicle and *n* = 9 in RPh201 treatment group) and Sham rats (*n* = 5) were transcardially perfused with 0.9% saline and 4% paraformaldehyde 133 days after MCAO or Sham operation, respectively. Brains were fixed in 4% paraformaldehyde and embedded in paraffin. A series of coronal sections (6 μm) were cut for histology and immunohistochemistry analysis. Infarct volume was measured on Hematoxylin & Eosin stained coronal sections, as previously described ([@B43]).

Immunohistochemistry Analysis {#S2.SS8}
-----------------------------

Immunohistochemistry was performed on brain coronal sections within the MCA territory (bregma 0 to −1.4 mm) obtained from rats sacrificed 133 days after ischemia and Sham operation. The following antibodies were used: rat anti-Myelin basic protein (MBP, Millipore), chicken anti-Neurofilament heavy chain (NFH, ThermoFisher Scientific), rabbit anti-Synaptophysin (Abcam), for quantification of MBP, NFH, and Synaptophysin immunoreactivity. Immunoreactive areas were digitized throughout the peri-infarct area, as well as the corresponding contralateral homologous areas. The peri-infarct area was defined as a strip of cerebral tissue (300 μm in width) along the medial border of the infarct cavity ([@B37]). Data are presented as the percentage of immunoreactive area at the peri-infarct region relative to the contralateral homologous region on the same section. Additional antibodies used for immunohistochemistry were: BrdU (Dako), Doublecortin (DCX, Abcam), Microtube associated protein 2 (MAP2, Aves Labs), Glial fibrillary acidic protein (GFAP, Dako), Ionized calcium binding adaptor molecule 1 (IBA1, Wako Chemicals), and CD-31 (R&D Systems). The density of BrdU-immunoreactive cells, the percentage DCX-immunoreactive area, and the percentage of BrdU and DCX double-labeled cells within the ipsilateral subventricular zone (SVZ) and peri-infarct area were measured. The number of IBA1 immunoreactive cells and the areas for MAP2 and GFAP throughout the peri-infarct area were measured. The density of CD-31 immunoreactive vessels and the percentage of BrdU and CD-31 double-labeled cells throughout the peri-infarct area was measured.

Western Blot Analysis {#S2.SS9}
---------------------

Brain tissues were collected for rats enrolled into the 2 week treatment cohort at 35 days after MCAO (*n* = 5/Vehicle, *n* = 4/RPh201, and *n* = 4/Sham), and for rats enrolled into the 16 week treatment cohort at 133 days after MCAO (*n* = 5/Vehicle, *n* = 5/RPh201 treatment, and *n* = 4/Sham). Briefly, rats were decapitated under deep anesthesia. Brains were separated into left and right hemisphere and flash-frozen at −80°C for subsequent protein extraction. Total proteins were extracted for Western blots. The following primary antibodies were employed: rat anti-Myelin basic protein (MBP, Millipore), chicken anti-Neurofilament heavy chain (NFH, ThermoFisher Scientific), and rabbit anti-Synaptophysin (Abcam). The protein levels of MBP, NFH, and Synaptophysin were determined by Western blot analysis. Additional antibodies used for Western blot analysis were: Vascular endothelial growth factor receptor (VEGFR, Abcam), Intercellular adhesion molecule 1 (ICAM, Cell Signaling), Toll-like receptor-2 (TLR2, Abcam), and Toll-like receptor-4 (TLR4, Abcam).

Statistical Analysis {#S2.SS10}
--------------------

Data were evaluated for normality, and ranked data or non-parametric Kruskal--Wallis test were used for data that were not normally distributed. For the safety evaluation, the log rank test/Kaplan-Meier was used to analyze mortality difference between RPh201 and Vehicle treated groups. The Global test using Generalize Estimating Equation (GEE, PROC GENMOD in SAS 9.4.) were implemented to test the treatment effect on the behavioral outcome measured from three behavioral tests at each time point ([@B40]). Treatment effect was tested on individual outcome only if the Global test was significant at the 0.05 level. The one-way ANOVA was used to test the treatment effects on histology, immunohistochemistry, and Western blot measurements.

Results {#S3}
=======

Mortality and Safety {#S3.SS1}
--------------------

Prior to initiation of treatment, four rats (1 from RPh201 group and 3 from Vehicle group) died within 21 days after MCAO and these rats were excluded from further evaluation. During the treatment, one rat treated with RPh201 died at 7 days after initiation of treatment, while no rats died in the Vehicle group. Log rank test showed there were no significant (*p* = 0.79) survival differences between RPh201 and Vehicle groups. All ischemic rats lost body weight over the first week after MCAO, but gradually regained weight over time at a similar rate between the two groups. There was no treatment effect on body weight (*p* = 0.583) in the ischemic rats.

RPh201 Treatment Improves Functional Recovery {#S3.SS2}
---------------------------------------------

The Global test revealed that Sham operated animals did not show any neurological deficits throughout the experiments; however, all ischemic rats exhibited neurological functional deficits measured by mNSS, adhesive removal test, and foot-fault test prior to the treatment (at 1, 7, 14, and 21 days after MCAO), which were comparable between RPh201 and Vehicle groups, indicating that the baseline neurological functions were balanced among groups. The RPh201 treatment significantly reduced neurological deficits starting from day 90 and persisting to day 120 after MCAO compared to the Vehicle treatment ([Figure 1](#F1){ref-type="fig"}).

![The effect of RPh201 on neurological outcome. Neurological outcome measured by mNSS, adhesive removal test, and foot-fault test in ischemic rats treated with RPh201 and Vehicle. Values are mean ± SE. \*^,\ +^*p* \< 0.05 compared with the Vehicle group.](fnins-14-00813-g001){#F1}

Histopathological analysis showed that there were no significant differences of infarct volume (*p* = 0.5) between the rats treated with RPh201 (30 ± 12.4%, *n* = 9) and Vehicle (25.9 ± 10.1%, *n* = 7). No ischemic lesion was observed in sham operated animals.

RPh201 Treatment Increases Axonal and Myelin Densities After Stroke {#S3.SS3}
-------------------------------------------------------------------

Neuronal and myelin remodeling contributes to stroke recovery ([@B14]; [@B42]; [@B44]; [@B16]). We thus, examined the effect of RPh201 on axons, dendrites, and myelin. Immunohistochemical staining analysis showed that the RPh201 treatment significantly increased the densities of NFH+ axons and dendrites and MBP+ myelin in the peri-infarct region 133 days after MCAO compared with the Vehicle treatment ([Figure 2](#F2){ref-type="fig"}). However, the RPh201 treatment did not significantly affect synaptophysin+ synapse density in peri-infarct area (47 ± 5%) compared with the Vehicle (56 ± 4%). No statistically significant differences were detected in BrdU, DCX, MAP2, IBA1, GFAP, CD-31 immunoreactivities between RPh201 and Vehicle treatment groups (data not shown). Western blot analysis showed that the RPh201 treatment significantly increased MBP protein levels in the ipsilateral hemisphere compared with the Vehicle treatment at 35 and 133 days after MCAO ([Figure 3](#F3){ref-type="fig"}). Moreover, RPh201 treatment significantly increased the ipsilateral synaptophysin levels at 35 days but not at 133 days after MCAO, compared with the Vehicle treatment. However, the ipsilateral NFH protein levels were not significantly different at 35 and 133 days after MCAO between RPh201 and Vehicle groups (*P* = 0.79, data not shown). In addition, no differences were detected in ipsilateral hemispheric VEGFR, ICAM1, TLR2, and TLR4 levels between RPh201 and Vehicle groups (data not shown).

![The effect of RPh201 on NFH and MBP immunoreactivity. Panels in **(A)** are the representative images of H&E stained coronal brain sections obtained from ischemic rats after 16 weeks of Vehicle and RPh201 treatments. The peri-infarct area in each section is outlined in black. Panels in **(B)** are the double immunofluorescent images of NFH (green) and MBP (red) immunoreactivity within the peri-infarct areas (boxed areas in **A**) acquired from adjacent coronal sections from **(A)**. Bar graphs are the quantitative data of NFH **(C)** and MBP **(D)** immunoreactive areas in the peri-infarct region. IC: ischemic core. Bar = 100 μm. Values are mean ± SE. \**p* \< 0.05.](fnins-14-00813-g002){#F2}

![The effects of RPh201 on protein levels of MBP and synaptophysin. Representative Western blot images **(A)**, and quantitative date of MBP **(B)** and Synaptophysin **(C)** proteins in brain tissue after 2 and 16 weeks of RPh201 and Vehicle treatment.](fnins-14-00813-g003){#F3}

Discussion {#S4}
==========

Our data for the first time demonstrated that administration of RPh201 initiated 3 weeks after stroke onset improves neurological functions. The RPh201 increased neuronal and myelination remodeling likely contributes to improved long-term stroke recovery.

Following ischemic stroke, oxidative stress and the inflammatory response are key pathological mechanisms that escalate brain damage. Treatment strategies that inhibit oxidative stress and inflammatory response following stroke may confer neuroprotection. Thus, a neuroprotective effect of RPh201 can be speculated. However, the RPh201 treatment initiated 21 days after MCAO did not reduce infarction, which is expected because infarction matures during 7 and 14 days after MCAO ([@B5]; [@B9]). These data suggest that the delayed (21 days) RPh201 induced improvement of neurological function is unlikely to result from its neuroprotective effects, but is likely attributed to the effect of RPh201 on enhancing recovery.

Stroke stimulates coordinated white matter remodeling processes including remyelination of demyelinated axons, axonal reorganization/regeneration, and synaptic formations, all of which in concert, contribute to stroke recovery ([@B26]; [@B7]). Stroke induced white matter remodeling/repair processes are heightened within first few weeks after stroke onset, a period during which most robust recovery occurs ([@B3]; [@B20]; [@B18]). For example, remyelination occurs in the peri-infarct region starting a few days after stroke ([@B23]; [@B11]; [@B36]; [@B1]; [@B25]), whereas axonal spouting is present within 2 weeks, and elevation of peri-infarct synaptogenesis persists for 2 months after stroke onset ([@B35]). However, these spontaneous remodeling processes are limited. The present study showed that the RPh201 treatment significantly increased axonal and myelination densities in peri-infarct regions assessed by immunohistochemistry analysis 133 days after MCAO. Additionally, Western blot analysis revealed that RPh201 treatment augmented myelination and synaptic plasticity, demonstrated by elevation of MBP and Synaptophysin proteins as early as 35 days after MCAO, respectively. However, Western blot analysis did not detect a significant increase in NFH protein levels following the RPh201 treatment, which likely reflects differences of the two methods used to analyze proteins. The Western blot analysis was performed on bulk proteins extracted from the entire hemisphere tissue, while immunohistochemistry was done at the cellular level. Thus, immunohistochemistry provides a more sensitive method to detect differences of NFH levels in the peri-infarct regions between the treatment and vehicle group. Nevertheless, the present study suggests that RPh201 amplifies ischemic brain remodeling. Importantly, increase of MBP and Synaptophysin proteins by RPh201 occurs prior to significant improvement of neurological function that became apparent at 90--120 days after MCAO, suggesting that RPh201 amplified axonal and myelination remodeling in ischemic brain contributes to improved functional outcome. The effect of RPh201 on synaptophysin protein appears transient in which a significant augmentation was detected at 35 days, but not 133 days after MCAO. Additional experiments are warranted to investigate how RPh201 affects synaptophysin.

There are several limitations in the present study. First, the effect of RPh201 on cognitive function was not evaluated. Clearly, stroke induces long-term sensorimotor and cognitive dysfunction, and white matter remodeling after stroke is critical for cognitive performance ([@B38]). Thus, additional validation studies are warranted. Secondly, only young male rats were used in the present study, whereas stroke is primarily occurs older population with sexually dimorphic ([@B32]; [@B24]). It remains to be investigated whether the current findings are applicable to ischemic aged rats, female rats, and animals with comorbid conditions. Thirdly, the present study did not assess the effect of RPh201 on temporal and spatial profiles of white matter remodeling, oligodendrogenesis, and the related activation of neuroinflammatory/neurotrophic factors. Finally, RPh201 is composed of a mixture of various constituents, including masticadienonic acid and isomasticadienonic acid ([@B12]). Currently, the leading active substances for RPh201 remain to be identified. Further work is required to identify the key components that are responsible for the therapeutic effect of RPh201 for stroke treatment. Although a full spectrum of potential beneficial effects of RPh201 for stroke warrants further investigation, the present study highlights that during the chronic recovery phase, ischemic brain remains receptive to RPh201 treatment which amplifies white matter remodeling and promotes long-term recovery.

In conclusion, our data demonstrated that delayed 21 days onset of treatment with RPh201 effectively improves long-term neurological function in rats after stroke. RPh201 is well tolerated in the clinical setting. With emerging recognition that the long-lasting brain remodeling capacities following CNS injuries contribute to functional recovery, our data suggest that RPh201 has potential to aid recovery of neurological function in stroke survivors.
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